pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Relistor
drug
save

methylnaltrexone bromide

Marketedupdated 3mo ago
by Salix Pharmaceuticals Ltd
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 3, 2027
349 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (27)

  • Mar 10, 2031formulationUS 103074174.6y
  • Mar 10, 2031formulationUS 103765054.6y
  • Mar 10, 2031formulationUS 85242764.6y
  • Mar 10, 2031formulationUS 89566514.6y
  • Mar 10, 2031formulationUS 93144614.6y
  • Dec 31, 2030method-of-use (U-1185)US 82474254.4y
  • Dec 31, 2030method-of-use (U-1185)US 82474254.4y
  • Dec 31, 2030method-of-use (U-1185)US 82474254.4y
  • Sep 30, 2029method-of-use (U-1185)US 84206633.1y
  • Sep 30, 2029method-of-use (U-1185)US 84206633.1y
  • Sep 30, 2029method-of-use (U-1185)US 84206633.1y
  • Sep 30, 2029method-of-use (U-1185)US 84206633.1y
  • Sep 30, 2029formulationUS 88224903.1y
  • Sep 30, 2029formulationUS 88224903.1y
  • Sep 30, 2029formulationUS 88224903.1y
  • Sep 30, 2029formulationUS 91801253.1y
  • Sep 30, 2029formulationUS 91801253.1y
  • Sep 30, 2029formulationUS 91801253.1y
  • Sep 30, 2029formulationUS 91801253.1y
  • Sep 30, 2029formulationUS 94924453.1y
  • Sep 30, 2029formulationUS 94924453.1y
  • Sep 30, 2029formulationUS 94924453.1y
  • Sep 30, 2029formulationUS 94924453.1y
  • Sep 30, 2029formulationUS 97243433.1y
  • Aug 3, 2027formulationUS 12303592349d
  • Aug 3, 2027formulationUS 12303592349d
  • Aug 3, 2027formulationUS 12303592349d

News(0)

no news has mentioned this drug yet

brand
Relistor
generic
methylnaltrexone bromide
indication
Opioid-Induced Constipation (OIC)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 24m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?